2026 年第 4 期 第 21 卷

清热利肺口服液联合重组人干扰素α1b治疗儿童毛细支气管炎的效果及对血液流变学的影响

Efficacy of Qingre Lifei oral liquid combined with recombinant human interferon α1b in the treatment of bronchiolitis in children and its effect on hemorheology

作者：王楠1高建2王晓茜1史晓宇3白雪4

英文作者：Wang Nan1 Gao Jian2 Wang Xiaoqian1 Shi Xiaoyu3 Bai Xue4

单位：1北京中医药大学第三附属医院药学部，北京100029；2北京市通州区第二医院药剂科，北京101102；3首都医科大学附属北京地坛医院药学部，北京100015；4北京中医药大学第三附属医院儿科，北京100029

英文单位：1Department of Pharmacy Beijing University of Chinese Medicine Third Affiliated Hospital Beijing 100029 China; 2Department of Pharmacy Tongzhou District Second Hospital of Beijing Beijing 101102 China; 3Department of Pharmacy Beijing Ditan Hospital Capital Medical University Beijing 100015 China; 4Department of Pediatrics Beijing University of Chinese Medicine Third Affiliated Hospital Beijing 100029 China

关键词：毛细支气管炎；重组人干扰素α1b；清热利肺口服液；炎症因子；血液流变学

英文关键词：Bronchiolitis;Recombinanthumaninterferonα1b;QingreLifeioralliquid;Inflammatoryfactors;Hemorheology

• 摘要：

• 目的 探讨清热利肺口服液联合重组人干扰素α1b治疗儿童毛细支气管炎的效果及对血液流变学的影响。方法 选择2022年12月至2023年12月北京中医药大学第三附属医院接诊的毛细支气管炎患儿296例。采用电脑随机数法分为观察组和对照组，各148例。对照组在支持治疗基础上经口或鼻雾化吸入重组人干扰素α1b治疗，观察组在对照组基础上口服清热利肺口服液治疗，2组均连续治疗7 d。比较2组的症状体征消失时间、肺功能、炎症因子、血液流变学指标、疗效及不良反应。结果 观察组患儿的咳嗽、阵发性喘憋、鼻翼煽动及三凹征消失时间均短于对照组（均P＜0.05）。治疗后，观察组的吸气呼气时间比、达峰容积比和γ干扰素均显著高于对照组，呼吸阻力、白细胞介素33、嗜酸性粒细胞、血浆黏度、红细胞聚集指数和纤维蛋白原均显著低于对照组（均P＜0.05）。观察组治疗有效率高于对照组［96.6%（143/148）比89.2%（132/148）］（P=0.013）。治疗期间2组患儿未见严重不良反应。结论 清热利肺口服液联合重组人干扰素α1b治疗儿童毛细支气管炎，有助于减轻呼吸道症状，抑制气道炎症，调节血液流变学，效果及安全性良好。

• Objective To investigate the efficacy of Qingre Lifei oral liquid combined with recombinant human interferon α1b in the treatment of bronchiolitis in children and its effect on hemorheology. Methods A total of 296 children with bronchiolitis admitted to Beijing University of Chinese Medicine Third Affiliated Hospital from December 2022 to December 2023 were selected and randomly divided into the observation group and the control group with 148 cases in each group by computer random number method. The control group was treated with nebulized inhalation of recombinant human interferon α1b via oral or nasal route on the basis of supportive therapy, and the observation group was treated with oral Qingre Lifei oral liquid on the basis of the control group. Both groups were treated continuously for 7 d. The disappearance time of symptoms and signs, lung function, inflammatory factors, hemorheological indexes, therapeutic efficacy and adverse reactions were compared between the two groups. Results The disappearance time of cough, paroxysmal dyspnea, nasal flaring and three concave signs in the observation group was shorter than that in the control group (all P＜0.05). After treatment, the inspiratory to expiratory time ratio, time to peak tidal volume ratio and interferon-γ in the observation group were significantly higher than those in the control group, while respiratory resistance, interleukin-33, eosinophils, plasma viscosity, erythrocyte aggregation index and fibrinogen were significantly lower than those in the control group (all P＜0.05). The total effective rate of the observation group was higher than that of the control group ［96.6%(143/148) vs 89.2%(132/148)］(P=0.013). No severe adverse reactions were observed in both groups during the treatment period. Conclusion Qingre Lifei oral liquid combined with recombinant human interferon α1b in the treatment of bronchiolitis in children is helpful to alleviate respiratory symptoms, inhibit airway inflammation and regulate hemorheology, with good efficacy and safety.